• SVB Leerink maintains an Outperform rating on Relmada Therapeutics Inc (NASDAQ: RLMD) shares as the Human Liability Potential study data was about "as good as we could have hoped for," with no evidence of abuse potential.

• Analyst Marc Goodman believes this data should give confidence to the investment community that REL-1017 will probably end up as a Schedule IV or V, which would be great news.

• Several experts confirmed that the data was supportive of this low scheduling on the conference call, Goodman adds.

• Given the weak stock performance recently, the analyst would expect Relmada to bounce back and move into the $35-$40 range in the near term.

• Truist raised the price target on Relmada to $90 from $75 and kept a Buy rating (upside of more than 250%).

• Analyst Joon Lee notes that the HAP study comparing REL-1017 against IV ketamine is expected to start in 2H21.

• The management expects similar likability scores for REL-1017, while IV Ketamine is likely to yield a likability score over 65, implying that 25mg and 75mg will likely separate with statistical significance.

• Price Action: RLMD shares are down 3.86% at $24.15 during the market session on the last check Tuesday.

Latest Ratings for RLMD

View More Analyst Ratings for RLMD
View the Latest Analyst Ratings

See more from Benzinga

• Click here for options trades from Benzinga

• Relmada's Stock Moves Higher As Its Major Depressive Disorder Candidate Shows Lack Of Abuse Potential

• Relmada Therapeutics In-Licenses Psilocybin Program From Arbormentis

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.